Q2 EPS Forecast for Rigel Pharmaceuticals Lowered by Analyst

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Stock analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a research note issued to investors on Wednesday, May 6th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of $1.11 for the quarter, down from their prior estimate of $1.20. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $4.25 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q3 2026 earnings at $1.18 EPS and Q4 2026 earnings at $1.26 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.36). The firm had revenue of $58.82 million during the quarter, compared to the consensus estimate of $62.40 million. Rigel Pharmaceuticals had a net margin of 121.50% and a return on equity of 60.34%.

Other research analysts have also issued reports about the company. Zacks Research upgraded Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 18th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research report on Tuesday, April 21st. Citigroup reiterated a “buy” rating on shares of Rigel Pharmaceuticals in a research report on Wednesday, January 14th. Finally, Wall Street Zen lowered Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.67.

Rigel Pharmaceuticals Stock Down 5.1%

Shares of RIGL opened at $26.67 on Thursday. The firm has a market capitalization of $492.86 million, a price-to-earnings ratio of 1.42 and a beta of 1.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.30 and a current ratio of 2.42. The business’s fifty day moving average price is $29.24 and its two-hundred day moving average price is $35.56. Rigel Pharmaceuticals has a 52 week low of $16.88 and a 52 week high of $52.24.

Insider Buying and Selling

In related news, Director Walter H. Moos sold 4,000 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $36.36, for a total transaction of $145,440.00. Following the sale, the director owned 12,722 shares of the company’s stock, valued at approximately $462,571.92. This trade represents a 23.92% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.47% of the company’s stock.

Institutional Trading of Rigel Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. AlphaQuest LLC raised its stake in shares of Rigel Pharmaceuticals by 234.8% in the 3rd quarter. AlphaQuest LLC now owns 1,105 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 775 shares during the period. IFP Advisors Inc bought a new stake in shares of Rigel Pharmaceuticals in the third quarter valued at about $55,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Rigel Pharmaceuticals by 400.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,275 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 1,020 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Rigel Pharmaceuticals in the third quarter valued at about $62,000. Finally, Wexford Capital LP acquired a new stake in Rigel Pharmaceuticals in the 3rd quarter valued at approximately $66,000. Institutional investors and hedge funds own 66.23% of the company’s stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).